title: The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey.
abstract: HP 749 was absorbed slowly in the conscious monkey after single oral doses (10, 20, and 40 mg/kg), with gradual metabolism to the N-despropyl metabolite, P86-7480. The tmax was 2 to 4 hours after dosing, with nonlinear increases in Cmax and the AUC0-4th for HP 749. The calculated elimination half life (t1/2) after oral administration was 7.4 +/- 2.1 hours; however, absorption appeared to influence the terminal phase because the t1/2 after intravenous administration of 10 mg/kg was 1.5 hours. Plasma concentration of HP 749 2 minutes after intravenous bolus was 26.08 micrograms/mL. The HP 749 was rapidly distributed (t1/2 alpha = 0.064 +/- 0.033 hours) after intravenous administration, and displayed a VZ of 2.6 +/- 0.85 L/kg. The CL of HP 749 was 20.8 +/- 6.9 mL/min/kg, whereas renal clearance (CLR) of unchanged drug was only 0.13 +/- 0.04 mL/min/kg. Thus, only about 1% of the administered dose was excreted unchanged by the kidney. The P86-7480 also was rapidly distributed and eliminated after an intravenous bolus, but was less extensively distributed than HP 749. HP 749 administered either as an intravenous bolus or orally caused a significant pressor effect soon after dosing. A significant tachycardia resulted from intravenous administration, but not after oral administration of the drug. An intravenous bolus of P86-7480 (0.1 mg/kg) resulted in an immediate increase in MAP and decreased heart rate. The duration of these cardiovascular events was significantly shorter after intravenous administration of P86-7480 than with intravenous or oral administration of the parent drug.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Research and New Drug Development, Hoechst-Roussel Pharmaceuticals Inc., Somerville, New Jersey 08876, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Hubbard
authors.forename: R S
authors.initials: RS
authors.lastname: Hsu
authors.forename: L
authors.initials: L
authors.lastname: Griffiths
authors.forename: C
authors.initials: C
authors.lastname: Natarajan
authors.forename: R
authors.initials: R
authors.lastname: Dean
authors.forename: E M
authors.initials: EM
authors.lastname: Dileo
authors.forename: T H
authors.initials: TH
authors.lastname: Hintze
mesh_terms: D000284:Administration, Oral; D000544:Alzheimer Disease / Q000188:drug therapy; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D016292:Procedural Sedation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006207:Half-Life; D007211:Indoles / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D007275:Injections, Intravenous; D007649:Ketamine; D008252:Macaca fascicularis; D008657:Metabolic Clearance Rate; D010276:Parasympatholytics / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D011725:Pyridines / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000494:pharmacology; D013610:Tachycardia / Q000139:chemically induced
chemical_list: D007211:Indoles; D010276:Parasympatholytics; D011725:Pyridines; C096037:N-(4-pyridinyl)-1H-indol-1-amine; D007649:Ketamine; C074872:besipirdine